Highlights Arcellx, Inc.

Equities

ACLX

US03940C1009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
50.02 ^USD	-2.13%		-8.12%	-9.87%

Apr. 18	Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing	MT
Apr. 03	Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (ACLX) ARCELLX Posts Q4 Revenue $63.1M	Feb. 28	MT
Arcellx, Inc. Enters an Assignment of Lease with A Third Party Sublessee	Jan. 31	CI
Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash	Dec. 08	CI
Arcellx Expands Partnership With Gilead Unit Kite	Nov. 15	MT
Arcellx, Inc. and Kite Announces Expansion in Strategic Partnership	Nov. 15	CI
Arcellx Q3 Net Loss Narrows	Nov. 13	MT
Earnings Flash (ACLX) ARCELLX Reports Q3 Revenue $15M	Nov. 13	MT
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition	Nov. 02	CI
Arcellx Says FDA Lifts Clinical Hold On Investigational Drug to Treat Multiple Myeloma; Shares Rise	23-08-14	MT
Earnings Flash (ACLX) ARCELLX Posts Q2 Revenue $14.3M	23-08-14	MT
Arcellx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program	23-08-14	CI
Arcellx Says US FDA Placed Clinical Hold on Multiple Myeloma Therapy Phase 2 Trial Following Patient Death	23-06-20	MT
Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program	23-06-19	CI
ARCELLX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-08	AQ
Earnings Flash (ACLX) ARCELLX Posts Q1 Revenue $17.9M	23-05-08	MT
Arcellx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
ARCELLX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arcellx, Inc.

Equities

ACLX

US03940C1009

Highlights

Filters